AI-PIA · Digital health & life sciences
AI Privacy Impact Assessment for Medical Device Makers
An AI Privacy Impact Assessment for a device maker examines what a machine-learning-enabled diagnostic or monitoring algorithm does with patient data that a standard PIA does not fully capture: how training data was sourced, whether the model performs consistently across patient subgroups, and what happens to privacy risk once the algorithm adapts after deployment. Work usually starts alongside an MLMD-class filing or when a hospital customer's own PIA process asks pointed questions about the model your device runs. An AI-PIA complements that regulatory filing; it does not replace it.
Reviewed by the Privacy Horizon team · Last reviewed
What you're protecting
What an AI-PIA has to examine in an adaptive diagnostic model
The privacy questions here go beyond where data is stored, into how the model itself was built and how it keeps changing.
Training data provenance and consent basis
Where the data used to train the algorithm actually came from, and whether the original consent or legal basis covers this specific use, especially where data was collected for one purpose and later reused for model training.
Model drift and adaptation
How the algorithm changes after deployment, and whether that change is governed by a predetermined change control plan that keeps the model within the bounds originally assessed.
Bias across patient subgroups
Whether the model performs consistently across age, sex, ethnicity or other relevant patient characteristics, and where performance gaps could translate into unequal clinical outcomes.
Explainability for clinicians
Whether clinicians using the device's output can understand enough about how a result was produced to exercise appropriate clinical judgment rather than defer to the algorithm by default.
Regulatory map
Where an AI-PIA sits alongside your regulatory filing
The AI-PIA is a privacy and bias analysis that runs parallel to, and feeds evidence into, your regulatory submission rather than substituting for it.
Health Canada's guidance for machine learning-enabled devices
Health Canada maintains guidance addressing the classification and premarket expectations for machine learning-enabled medical devices, into which privacy and bias analysis is a natural, complementary input.
Predetermined change control as the technical anchor
The predetermined change control concept, which defines the bounds within which a model may adapt without a new submission, gives the AI-PIA a concrete boundary to assess privacy and bias risk against.
PIPEDA's purpose-limitation principle
Reusing patient data collected for clinical care as training data for a commercial algorithm raises a purpose-limitation question the AI-PIA has to address directly, not assume away.
Provincial PIA obligations naming the model specifically
A hospital's Alberta HIA or BC FIPPA privacy impact assessment for an AI-enabled device may need model-specific detail about training data and bias testing that only you can supply.
What goes wrong
What the assessment is designed to catch before deployment
The risks here compound quietly, since a model that performs well on average can still fail specific patients badly.
Bias against underrepresented patient subgroups
A model trained predominantly on one demographic can underperform for others in ways that only surface once real-world outcome data accumulates, well after deployment.
Drift beyond the original change control bounds
An adaptive model that shifts its behaviour past what was originally assessed can change the privacy and bias picture without anyone formally re-evaluating it.
Training data reused beyond its consented purpose
Patient data collected during clinical care, repurposed for algorithm training without a clear legal basis, creates a purpose-limitation gap that surfaces during a hospital's own PIA review.
Our ai-pia for medical device makers
What our AI-PIA covers for an MLMD-class device
A structured review of data handling, bias and change control, producing evidence that strengthens your regulatory filing rather than duplicating it.
Data handling review of the training and inference pipeline
How training data moves from source through preprocessing to the model, and how inference-time patient data is handled once the device is deployed.
Bias and subgroup performance review
Analysis of where the model's performance may vary across patient subgroups, and what that means for how the device should be used and communicated to clinicians.
Predetermined change control documentation review
Assessment of whether the documented bounds for model adaptation adequately address privacy and bias risk as the model continues to learn.
Regulatory alignment overview
A broad comparison of your privacy and bias practices against emerging AI-in-health expectations, framed to support, not replace, the MLMD filing itself.
Ethical and responsible-use guidance
High-level principles for responsible AI use specific to a diagnostic or monitoring context, useful for clinician-facing communication and internal governance.
How the engagement runs
How an AI-PIA is built for an adaptive diagnostic algorithm
We work from the model's actual data pipeline and change control plan, not a generic AI checklist.
Step 1
Map training data provenance and consent
We trace where training data originated, what consent or legal basis applies, and where a purpose-limitation gap might exist.
Step 2
Assess bias across patient subgroups
We review available performance data across relevant patient characteristics to identify where outcomes may diverge meaningfully.
Step 3
Review the change control plan
We evaluate whether the documented bounds for post-deployment adaptation adequately account for privacy and bias risk as the model evolves.
Step 4
Produce the alignment overview and guidance
Findings are delivered as a document your RA/QA team can reference alongside the MLMD filing, plus responsible-use guidance for clinician communication.
What it costs
What determines AI-PIA cost for an adaptive diagnostic device
Cost depends on how complex and adaptive the algorithm is, whether a predetermined change control plan already exists to assess against, and how many jurisdictions have hospital customers whose own PIA process will need model-specific detail from you.
A model with a mature change control plan and documented training data provenance costs less to assess than one where those artifacts have to be reconstructed first. We scope pricing after reviewing your model documentation and the regulatory filing timeline it needs to support.
Medical Device Makers: AI-PIA questions, answered
It adds a structured privacy and bias analysis of how the model's adaptation affects patient data handling and subgroup outcomes, evidence that strengthens the filing without duplicating the clinical validation work Health Canada's MLMD process already requires. The two run in parallel rather than one substituting for the other.
Start by profiling the training data population against the patients the device will actually be used on, then examine available performance data across relevant subgroups such as age, sex or ethnicity. Where performance gaps appear, they need to be documented and factored into labelling and clinician guidance.
No. Clinical validation demonstrates the device works safely and effectively for its intended use, a distinct regulatory requirement. An AI-PIA examines privacy and bias risk in how the model handles patient data, complementary evidence that sits alongside, not inside, the clinical validation package.
Not for every routine retraining cycle within an established change control plan, but a material change to training data sources, model architecture, or intended patient population warrants a fresh look. The change control plan itself should define what triggers that reassessment.
An imaging AI's bias assessment focuses heavily on training image diversity across patient anatomy and demographics, while a monitoring-alert AI's assessment looks more at whether alert thresholds perform consistently across physiological baselines that vary by patient group. Both need subgroup-level evidence, but the data being examined differs substantially.
More for medical device makers
Other services for this niche
About this service
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.